Vimarsana
Biggest News Aggregation in the World

Page 32 - Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Tumors Today - Breaking & Trending Today

Landscape Surrounding HER2 ADCs in GI Cancers - Vimarsana News

Landscape Surrounding HER2 ADCs in GI Cancers

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

J&J: new data in genitourinary cancers -January 25, 2024 at 09:34 am EST - Vimarsana News

J&J: new data in genitourinary cancers -January 25, 2024 at 09:34 am EST

Johnson & Johnson announced today that new clinical and real-world data will be presented via 18 abstracts at the ASCO GU symposium being held January 25-27 in San Francisco, underlining the company's...

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints - Vimarsana News

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

Source: yahoo.com
Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU - Vimarsana News

Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU

/PRNewswire/ -- Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year's ASCO GU Symposium...

Sirnaomics Publishes Research on Cancer Drug Candidate - Vimarsana News

Sirnaomics Publishes Research on Cancer Drug Candidate

By Karen E. Roman Sirnaomics Ltd., a biopharmaceutical company developing RNAi therapeutics, recently published a research article showing a cancer drug candidate to treat solid tumors. The article focused on the company’s clinical studies with STP707, a polypeptide nanoparticle formulation, and provided a foundation for further research to treat hepatocellular carcinoma and other solid tumors, […]

Source: yahoo.com